Medtronic automated insulin pump named one of year’s ‘world-changing ideas’

Michael Walter | May 22, 2024 | Cardiovascular Business | Heart Health

Medtronic’s MiniMed 780G automated insulin delivery system. Image courtesy of Medtronic.

Fast Company, the New York-based business magazine, has named Medtronic’s MiniMed 780G automated insulin delivery system one of North America’s top world-changing ideas. This represents the fourth straight year a piece of Medtronic technology has been included in the annual list, which is designed to honor companies and products that address “the most pressing issues of our time.”

Fast Company’s 2024 World Changing Idea Awards highlighted a total of 12 finalists for its North America category, including the MiniMed 780G system.

“The recognition of the MiniMed 780G system as a World Changing Idea reflects our commitment to simplifying diabetes care and reducing the mental burden of this relentless disease,” Que Dallara, executive vice president and president of Medtronic Diabetes, said in a statement. “We're pleased to receive this honor and will keep working tirelessly to continue empowering individuals with the technology they need to thrive with type 1 diabetes.”

“Diabetes is a very personal disease and no two journeys are the same,” added Ali Dianaty, senior vice president of product innovation and operations with Medtronic Diabetes. “This recognition is a reflection of the tremendous dedication and commitment of the many cross-functional teams that worked day in and day out to bring an idea to life. The MiniMed 780G system is designed to adapt to each individual's unique needs and goals to help reduce the burden of diabetes management, so people with diabetes can spend more time doing what they love.”

The U.S. Food and Drug Administration (FDA) approved the MiniMed 790G device for patients with type 1 diabetes seven years old and older back in April 2023. One new feature available on the pump was meal detection technology, which can deliver insulin in those moments when the user loses track of time or underestimates how a meal may impact their health. According to Medtronic, this feature takes diabetes technology “one step closer to mimicking a healthy pancreas.”

The FDA’s approval was based in part on clinical data first shared with the public in June 2020. Researchers found that the MiniMed 780G was linked to a time in range of 78.8%.

Mammogram findings linked to heightened risk of CVD, type 2 diabetes and hypertension

Medtronic adds new AI models to its insertable cardiac monitors

Diabetes increases risk of death, complications when patients undergo CABG or PCI for left main disease

New formula could mean diabetes and weight loss drugs such as semaglutide are only needed every 4 months

Medtronic’s new insulin pump gains FDA approval

Abbott’s newest glucose monitoring device gains FDA clearance

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."